May 31, 2018 06:22 AM EDT
R&D

Gilead and Gala­pa­gos bag promis­ing PhII da­ta for star im­munol­o­gy drug fil­go­tinib — boost­ing late-stage fo­cus

John Carroll

Editor & Founder

Gilead $GILD and its part­ners at Gala­pa­gos $GLPG picked up some “very im­pres­sive” mid-stage da­ta for their star im­munol­o­gy drug fil­go­tinib, which hand­i­ly beat out …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times